A short social explainer from ABC7 Chicago on Lilly's experimental retatrutide and how it targets three hormones tied to appetite, with more at the station's link.
Recap by typeshit. Post by @abc7chicago on Instagram.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
Loading…